6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

LABA	NNP	laba	laba	laba	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Currently	RB	currently	currently	current	N	O
available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
inadequate	JJ	inadequate	inadequate	inadequ	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
drugs	NNS	drugs	drug	drug	N	O
mitigates	VBZ	mitigates	mitigates	mitig	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
from	IN	from	from	from	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
.	.	.	.	.	N	O

Available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
LABA	NNP	laba	laba	laba	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
and	CC	and	and	and	N	O
adolescent	JJ	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
large	JJ	large	large	larg	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
US	PRP	us	u	us	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
compared	VBN	compared	compared	compar	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
(	(	(	(	(	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
added	VBN	added	added	ad	N	O
to	TO	to	to	to	N	O
usual	JJ	usual	usual	usual	N	O
asthma	NN	asthma	asthma	asthma	Y	O
therapy	NN	therapy	therapy	therapi	N	O
showed	VBD	showed	showed	show	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

Systemic	NNP	systemic	systemic	system	N	O
and	CC	and	and	and	N	O
local	JJ	local	local	local	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
use	NN	use	use	use	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O

Candida	NNP	candida	candida	candida	N	B-AdverseReaction
albicans	VBZ	albicans	albicans	albican	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
COPD	NNP	copd	copd	copd	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Hypercorticism	NN	hypercorticism	hypercorticism	hypercortic	N	B-AdverseReaction
and	CC	and	and	and	N	O
adrenal	JJ	adrenal	adrenal	adren	N	B-AdverseReaction
suppression	NN	suppression	suppression	suppress	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)]	NN	)]	)]	)]	N	O

Reduction	NN	reduction	reduction	reduct	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
bone	JJ	bone	bone	bone	N	I-AdverseReaction
mineral	JJ	mineral	mineral	miner	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
)]	NN	)]	)]	)]	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O

:	:	:	:	:	N	O
COPD	NN	copd	copd	copd	Y	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
nasopharyngitis	JJ	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Asthma	NNS	asthma	asthma	asthma	Y	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
nasopharyngitis	JJ	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
GlaxoSmithKline	NNP	glaxosmithkline	glaxosmithkline	glaxosmithklin	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
825	CD	825	825	825	N	O
-	:	-	-	-	N	O
5249	CD	5249	5249	5249	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Obstructive	NNP	obstructive	obstructive	obstruct	N	O
Pulmonary	NNP	pulmonary	pulmonary	pulmonari	N	O
Disease	NNP	disease	disease	diseas	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
program	NN	program	program	program	N	O
for	IN	for	for	for	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
included	VBD	included	included	includ	N	O
7	CD	7	7	7	N	O
,	,	,	,	,	N	O
700	CD	700	700	700	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
lung	NN	lung	lung	lung	N	O
function	NN	function	function	function	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
two	CD	two	two	two	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
other	JJ	other	other	other	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
shorter	JJR	shorter	shorter	shorter	N	O
duration	NN	duration	duration	durat	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
034	CD	034	034	034	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
received	VBD	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
087	CD	087	087	087	N	O
subjects	NNS	subjects	subject	subject	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
strength	NN	strength	strength	strength	N	O
of	IN	of	of	of	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
confirmatory	NN	confirmatory	confirmatory	confirmatori	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
confirmatory	NN	confirmatory	confirmatory	confirmatori	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

6	CD	6	6	6	N	O
-	:	-	-	-	N	O
Month	NN	month	month	month	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
2	CD	2	2	2	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Trials	NNS	trials	trial	trial	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
;	:	;	;	;	N	O
n	CC	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
224	CD	224	224	224	N	O
and	CC	and	and	and	N	O
n	RB	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
030	CD	030	030	030	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
254	CD	254	254	254	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
70%	CD	70%	70%	70%	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
and	CC	and	and	and	N	O
84%	CD	84%	84%	84%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
.	.	.	.	.	N	O

They	PRP	they	they	they	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
62	CD	62	62	62	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
average	JJ	average	average	averag	N	O
smoking	JJ	smoking	smoking	smoke	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
44	CD	44	44	44	N	O
pack	NN	pack	pack	pack	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
54%	CD	54%	54%	54%	N	O
identified	VBN	identified	identified	identifi	N	O
as	IN	as	a	as	N	O
current	JJ	current	current	current	N	O
smokers	NNS	smokers	smoker	smoker	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
screening	NN	screening	screening	screen	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
postbronchodilator	NN	postbronchodilator	postbronchodilator	postbronchodil	N	O
percent	NN	percent	percent	percent	N	O
predicted	VBD	predicted	predicted	predict	N	O
FEV1was	NNP	fev1was	fev1was	fev1wa	N	O
48%	CD	48%	48%	48%	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
14%	CD	14%	14%	14%	N	O
to	TO	to	to	to	N	O
87%	CD	87%	87%	87%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
postbronchodilator	NN	postbronchodilator	postbronchodilator	postbronchodil	N	O
FEV1	NNP	fev1	fev1	fev1	N	O
forced	VBD	forced	forced	forc	N	O
vital	JJ	vital	vital	vital	N	O
capacity	NN	capacity	capacity	capac	N	O
(	(	(	(	(	N	O
FVC	NNP	fvc	fvc	fvc	N	O
)	)	)	)	)	N	O
ratio	NN	ratio	ratio	ratio	N	O
was	VBD	was	wa	wa	N	O
47%	CD	47%	47%	47%	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
17%	CD	17%	17%	17%	N	O
to	TO	to	to	to	N	O
88%	CD	88%	88%	88%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
percent	NN	percent	percent	percent	N	O
reversibility	NN	reversibility	reversibility	revers	N	O
was	VBD	was	wa	wa	N	O
14%	CD	14%	14%	14%	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
-	:	-	-	-	N	O
41%	CD	41%	41%	41%	N	O
to	TO	to	to	to	N	O
152%	CD	152%	152%	152%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Subjects	NNS	subjects	subject	subject	N	O
received	VBD	received	received	receiv	N	O
1	CD	1	1	1	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
once	RB	once	once	onc	N	O
daily	RB	daily	daily	daili	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
50	CD	50	50	50	N	O
mcg	NN	mcg	mcg	mcg	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
,	,	,	,	,	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
,	,	,	,	,	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
200	CD	200	200	200	N	O
mcg	NN	mcg	mcg	mcg	N	O
,	,	,	,	,	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
with	IN	with	with	with	N	O
3%	CD	3%	3%	3%	N	O
Incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
More	JJR	more	more	more	N	O
Common	NNP	common	common	common	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
Subjects	NNP	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Obstructive	NNP	obstructive	obstructive	obstruct	N	O
Pulmonary	NNP	pulmonary	pulmonary	pulmonari	N	O
Disease	NNP	disease	disease	diseas	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
410	CD	410	410	410	N	O
)	)	)	)	)	N	O
Vilanterol	NNP	vilanterol	vilanterol	vilanterol	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
408	CD	408	408	408	N	O
)	)	)	)	)	N	O
Fluticasone	CD	fluticasone	fluticasone	fluticason	N	O
Furoate	NNP	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
410	CD	410	410	410	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
412	CD	412	412	412	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction

9	CD	9	9	9	N	O
10	CD	10	10	10	N	O
8	CD	8	8	8	N	O
8	CD	8	8	8	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

7	CD	7	7	7	N	O
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
a	DT	a	a	a	N	O

5	CD	5	5	5	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

7	CD	7	7	7	N	O
9	CD	9	9	9	N	O
7	CD	7	7	7	N	O
5	CD	5	5	5	N	O

a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fungal	JJ	fungal	fungal	fungal	N	B-AdverseReaction
oropharyngitis	NN	oropharyngitis	oropharyngitis	oropharyng	Y	I-AdverseReaction
.	.	.	.	.	N	O

12	CD	12	12	12	N	O

-	:	-	-	-	N	O
Month	NN	month	month	month	N	O
Trials	NNS	trials	trial	trial	N	O

Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
two	CD	two	two	two	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Trials	NNS	trials	trial	trial	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
;	:	;	;	;	N	O
n	CC	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
633	CD	633	633	633	N	O
and	CC	and	and	and	N	O
n	RB	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
622	CD	622	622	622	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Trials	NNS	trials	trial	trial	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
included	VBD	included	included	includ	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
255	CD	255	255	255	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
57%	CD	57%	57%	57%	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
and	CC	and	and	and	N	O
85%	CD	85%	85%	85%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
.	.	.	.	.	N	O

They	PRP	they	they	they	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
64	CD	64	64	64	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
average	JJ	average	average	averag	N	O
smoking	JJ	smoking	smoking	smoke	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
46	CD	46	46	46	N	O
pack	NN	pack	pack	pack	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
44%	CD	44%	44%	44%	N	O
identified	VBN	identified	identified	identifi	N	O
as	IN	as	a	as	N	O
current	JJ	current	current	current	N	O
smokers	NNS	smokers	smoker	smoker	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
screening	NN	screening	screening	screen	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
postbronchodilator	NN	postbronchodilator	postbronchodilator	postbronchodil	N	O
percent	NN	percent	percent	percent	N	O
predicted	VBD	predicted	predicted	predict	N	O
FEV1was	NNP	fev1was	fev1was	fev1wa	N	O
45%	CD	45%	45%	45%	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
12%	CD	12%	12%	12%	N	O
to	TO	to	to	to	N	O
91%	CD	91%	91%	91%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
postbronchodilator	NN	postbronchodilator	postbronchodilator	postbronchodil	N	O
FEV1	NNP	fev1	fev1	fev1	N	O
FVC	NNP	fvc	fvc	fvc	N	O
ratio	NN	ratio	ratio	ratio	N	O
was	VBD	was	wa	wa	N	O
46%	CD	46%	46%	46%	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
17%	CD	17%	17%	17%	N	O
to	TO	to	to	to	N	O
81%	CD	81%	81%	81%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
indicating	VBG	indicating	indicating	indic	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
subject	JJ	subject	subject	subject	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
very	RB	very	very	veri	N	O
severely	RB	severely	severely	sever	N	O
impaired	JJ	impaired	impaired	impair	N	O
airflow	JJ	airflow	airflow	airflow	N	O
obstruction	NN	obstruction	obstruction	obstruct	Y	O
.	.	.	.	.	N	O

Subjects	NNS	subjects	subject	subject	N	O
received	VBD	received	received	receiv	N	O
1	CD	1	1	1	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
once	RB	once	once	onc	N	O
daily	RB	daily	daily	daili	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
50	CD	50	50	50	N	O
mcg	NN	mcg	mcg	mcg	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
806	CD	806	806	806	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
included	VBN	included	included	includ	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Asthma	NNP	asthma	asthma	asthma	Y	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
18	CD	18	18	18	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
parallel	JJ	parallel	parallel	parallel	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
4	CD	4	4	4	N	O
to	TO	to	to	to	N	O
76	CD	76	76	76	N	O
weeks	NNS	weeks	week	week	N	O
duration	NN	duration	duration	durat	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
9	CD	9	9	9	N	O
,	,	,	,	,	N	O
969	CD	969	969	969	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
369	CD	369	369	369	N	O
subjects	NNS	subjects	subject	subject	N	O
and	CC	and	and	and	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
956	CD	956	956	956	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
subjects	NNS	subjects	subject	subject	N	O
aged	VBD	aged	aged	age	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
were	VBD	were	were	were	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
age	NN	age	age	age	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.4	CD	8.4	8.4	8.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
two	CD	two	two	two	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
two	CD	two	two	two	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

12	CD	12	12	12	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Trials	NNS	trials	trial	trial	N	O

Trial	JJ	trial	trial	trial	N	O
1	CD	1	1	1	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
in	IN	in	in	in	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
and	CC	and	and	and	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
609	CD	609	609	609	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
58%	CD	58%	58%	58%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
84%	CD	84%	84%	84%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
40	CD	40	40	40	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
is	VBZ	is	is	is	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
with	IN	with	with	with	N	O
2%	CD	2%	2%	2%	N	O
Incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
More	JJR	more	more	more	N	O
Common	NNP	common	common	common	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
Subjects	NNP	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
Asthma	NNP	asthma	asthma	asthma	Y	O
(	(	(	(	(	N	O
Trial	NNP	trial	trial	trial	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
201	CD	201	201	201	N	O
)	)	)	)	)	N	O
Fluticasone	CD	fluticasone	fluticasone	fluticason	N	O
Furoate	NNP	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
205	CD	205	205	205	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
203	CD	203	203	203	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction

10	CD	10	10	10	N	O
7	CD	7	7	7	N	O
7	CD	7	7	7	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
a	DT	a	a	a	N	O

2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

5	CD	5	5	5	N	O
4	CD	4	4	4	N	O
4	CD	4	4	4	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction

2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Trial	NN	trial	trial	trial	N	O

2	CD	2	2	2	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
in	IN	in	in	in	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
and	CC	and	and	and	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
039	CD	039	039	039	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
60%	CD	60%	60%	60%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
88%	CD	88%	88%	88%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
46	CD	46	46	46	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
and	CC	and	and	and	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
is	VBZ	is	is	is	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
and	CC	and	and	and	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
with	IN	with	with	with	N	O
2%	CD	2%	2%	2%	N	O
Incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
Asthma	NNP	asthma	asthma	asthma	Y	O
(	(	(	(	(	N	O
Trial	NNP	trial	trial	trial	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
346	CD	346	346	346	N	O
)	)	)	)	)	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
346	CD	346	346	346	N	O
)	)	)	)	)	N	O
Fluticasone	CD	fluticasone	fluticasone	fluticason	N	O
Furoate	NNP	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
347	CD	347	347	347	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

8	CD	8	8	8	N	O
8	CD	8	8	8	N	O
9	CD	9	9	9	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction

7	CD	7	7	7	N	O
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O

Influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction

3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction

2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction

2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Cough	NN	cough	cough	cough	Y	B-AdverseReaction

1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

24	CD	24	24	24	N	O
-	:	-	-	-	N	O
Week	JJ	week	week	week	N	O
Trial	JJ	trial	trial	trial	N	O

Trial	NN	trial	trial	trial	N	O

3	CD	3	3	3	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
,	,	,	,	,	N	O
fluticasone	JJ	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
200	CD	200	200	200	N	O
mcg	NN	mcg	mcg	mcg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
propionate	NN	propionate	propionate	propion	N	O
500	CD	500	500	500	N	O
mcg	NN	mcg	mcg	mcg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
and	CC	and	and	and	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
586	CD	586	586	586	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
59%	CD	59%	59%	59%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
84%	CD	84%	84%	84%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
46	CD	46	46	46	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Tables	NNP	tables	table	tabl	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
included	VBD	included	included	includ	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
.	.	.	.	.	N	O

12	CD	12	12	12	N	O
-	:	-	-	-	N	O
Month	JJ	month	month	month	N	O
Trial	JJ	trial	trial	trial	N	O

Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
201	CD	201	201	201	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
202	CD	202	202	202	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
propionate	NN	propionate	propionate	propion	N	O
500	CD	500	500	500	N	O
mcg	NN	mcg	mcg	mcg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
100	CD	100	100	100	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
adolescent	NN	adolescent	adolescent	adolesc	N	O
and	CC	and	and	and	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
asthma	NN	asthma	asthma	asthma	Y	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
63%	CD	63%	63%	63%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
67%	CD	67%	67%	67%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
39	CD	39	39	39	N	O
years	NNS	years	year	year	N	O
;	:	;	;	;	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
(	(	(	(	(	N	O
aged	VBN	aged	aged	age	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
made	VBD	made	made	made	N	O
up	RP	up	up	up	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Tables	NNP	tables	table	tabl	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
or	CC	or	or	or	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
for	IN	for	for	for	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
included	VBN	included	included	includ	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
extrasystoles	NNS	extrasystoles	extrasystole	extrasystol	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	I-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
supraventricular	JJ	supraventricular	supraventricular	supraventricular	N	B-AdverseReaction
extrasystoles	NNS	extrasystoles	extrasystole	extrasystol	Y	I-AdverseReaction
,	,	,	,	,	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
extrasystoles	NNS	extrasystoles	extrasystole	extrasystol	Y	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
sinusitis	NN	sinusitis	sinusitis	sinus	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
Trial	NN	trial	trial	trial	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
76	CD	76	76	76	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
subjects	VBZ	subjects	subject	subject	N	O
received	VBN	received	received	receiv	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
009	CD	009	009	009	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
fluticasone	JJ	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
010	CD	010	010	010	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
Trial	JJ	trial	trial	trial	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Subjects	NNS	subjects	subject	subject	N	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	O
that	WDT	that	that	that	N	O
required	VBD	required	required	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
oral	JJ	oral	oral	oral	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
or	CC	or	or	or	N	O
emergency	NN	emergency	emergency	emerg	N	O
department	NN	department	department	depart	N	O
visit	NN	visit	visit	visit	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
-	:	-	-	-	N	O
patient	NN	patient	patient	patient	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
year	NN	year	year	year	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
trial	NN	trial	trial	trial	N	O
entry	NN	entry	entry	entri	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
67%	CD	67%	67%	67%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
73%	CD	73%	73%	73%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
42	CD	42	42	42	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
aged	VBN	aged	aged	age	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
made	VBD	made	made	made	N	O
up	RP	up	up	up	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
subjects	NNS	subjects	subject	subject	N	O
aged	VBD	aged	aged	age	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
were	VBD	were	were	were	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
age	NN	age	age	age	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.4	CD	8.4	8.4	8.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Asthma	NNP	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hospitalizations	NNS	hospitalizations	hospitalization	hospit	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
10	CD	10	10	10	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
7	CD	7	7	7	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
subjects	NNS	subjects	subject	subject	N	O
aged	VBN	aged	aged	age	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
asthma	SYM	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hospitalizations	NNS	hospitalizations	hospitalization	hospit	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
151	CD	151	151	151	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
0	CD	0	0	0	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
100	CD	100	100	100	N	O
mcg	NN	mcg	mcg	mcg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
130	CD	130	130	130	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
or	CC	or	or	or	N	O
asthma	SYM	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
intubations	NNS	intubations	intubation	intub	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
adverse	VB	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
from	IN	from	from	from	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
postapproval	JJ	postapproval	postapproval	postapprov	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
chosen	VBN	chosen	chosen	chosen	N	O
for	IN	for	for	for	N	O
inclusion	NN	inclusion	inclusion	inclus	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
either	DT	either	either	either	N	O
their	PRP$	their	their	their	N	O
seriousness	NN	seriousness	seriousness	serious	N	O
,	,	,	,	,	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
reporting	NN	reporting	reporting	report	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
causal	JJ	causal	causal	causal	N	O
connection	NN	connection	connection	connect	N	O
to	TO	to	to	to	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Palpitations	NNS	palpitations	palpitation	palpit	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
.	.	.	.	.	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction
.	.	.	.	.	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
.	.	.	.	.	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Nervousness	NN	nervousness	nervousness	nervous	Y	B-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ASTHMA	NNP	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
\n\n	NN	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ASTHMA	NNP	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
\n\n	NN	\n\n	\n\n	\n\n	N	O
Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	O
agonists	NNS	agonists	agonist	agonist	N	O
(	(	(	(	(	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
)	)	)	)	)	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
large	JJ	large	large	larg	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
US	PRP	us	u	us	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
compared	VBN	compared	compared	compar	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
(	(	(	(	(	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
added	VBN	added	added	ad	N	O
to	TO	to	to	to	N	O
usual	JJ	usual	usual	usual	N	O
asthma	NN	asthma	asthma	asthma	Y	O
therapy	NN	therapy	therapy	therapi	N	O
showed	VBD	showed	showed	show	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
with	IN	with	with	with	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
LABA	NNP	laba	laba	laba	N	O
.	.	.	.	.	N	O

Currently	RB	currently	currently	current	N	O
available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
inadequate	JJ	inadequate	inadequate	inadequ	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
(	(	(	(	(	N	O
ICS	NNP	ics	ic	ic	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
drugs	NNS	drugs	drug	drug	N	O
mitigates	VBZ	mitigates	mitigates	mitig	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
from	IN	from	from	from	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
.	.	.	.	.	N	O

Available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
LABA	NNP	laba	laba	laba	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
and	CC	and	and	and	N	O
adolescent	JJ	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
asthma	NN	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
only	RB	only	only	onli	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
not	RB	not	not	not	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
medication	NN	medication	medication	medic	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
whose	WP$	whose	whose	whose	N	O
disease	NN	disease	disease	diseas	N	O
severity	NN	severity	severity	sever	N	O
clearly	RB	clearly	clearly	clearli	N	O
warrants	NNS	warrants	warrant	warrant	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
both	DT	both	both	both	N	O
an	DT	an	an	an	N	O
inhaled	VBN	inhaled	inhaled	inhal	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
LABA	NNP	laba	laba	laba	N	O
.	.	.	.	.	N	O

Once	RB	once	once	onc	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
is	VBZ	is	is	is	N	O
achieved	VBN	achieved	achieved	achiev	N	O
and	CC	and	and	and	N	O
maintained	VBN	maintained	maintained	maintain	N	O
,	,	,	,	,	N	O
assess	IN	assess	ass	assess	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
at	IN	at	at	at	N	O
regular	JJ	regular	regular	regular	N	O
intervals	NNS	intervals	interval	interv	N	O
and	CC	and	and	and	N	O
step	VB	step	step	step	N	O
down	RB	down	down	down	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
)	)	)	)	)	N	O
if	IN	if	if	if	N	O
possible	JJ	possible	possible	possibl	N	O
without	IN	without	without	without	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
and	CC	and	and	and	N	O
maintain	VB	maintain	maintain	maintain	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
medication	NN	medication	medication	medic	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
asthma	NN	asthma	asthma	asthma	Y	O
is	VBZ	is	is	is	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
on	IN	on	on	on	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
medium	VB	medium	medium	medium	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ASTHMA	NNP	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	O
agonists	NNS	agonists	agonist	agonist	N	O
(	(	(	(	(	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
)	)	)	)	)	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
,	,	,	,	,	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
(	(	(	(	(	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
)	)	)	)	)	N	O
showed	VBD	showed	showed	show	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
with	IN	with	with	with	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
LABA	NNP	laba	laba	laba	N	O
.	.	.	.	.	N	O

Currently	RB	currently	currently	current	N	O
available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
inadequate	JJ	inadequate	inadequate	inadequ	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
(	(	(	(	(	N	O
ICS	NNP	ics	ic	ic	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
drugs	NNS	drugs	drug	drug	N	O
mitigates	VBZ	mitigates	mitigates	mitig	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
from	IN	from	from	from	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
.	.	.	.	.	N	O

Available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
LABA	NNP	laba	laba	laba	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
and	CC	and	and	and	N	O
adolescent	JJ	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
When	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
asthma	NN	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
only	RB	only	only	onli	N	O
prescribe	VBZ	prescribe	prescribe	prescrib	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
not	RB	not	not	not	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
medication	NN	medication	medication	medic	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
ICS	NNP	ics	ic	ic	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
whose	WP$	whose	whose	whose	N	O
disease	NN	disease	disease	diseas	N	O
severity	NN	severity	severity	sever	N	O
clearly	RB	clearly	clearly	clearli	N	O
warrants	NNS	warrants	warrant	warrant	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
both	DT	both	both	both	N	O
an	DT	an	an	an	N	O
ICS	NNP	ics	ic	ic	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
LABA	NNP	laba	laba	laba	N	O
.	.	.	.	.	N	O

Once	RB	once	once	onc	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
is	VBZ	is	is	is	N	O
achieved	VBN	achieved	achieved	achiev	N	O
and	CC	and	and	and	N	O
maintained	VBN	maintained	maintained	maintain	N	O
,	,	,	,	,	N	O
assess	IN	assess	ass	assess	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
at	IN	at	at	at	N	O
regular	JJ	regular	regular	regular	N	O
intervals	NNS	intervals	interval	interv	N	O
and	CC	and	and	and	N	O
step	VB	step	step	step	N	O
down	RB	down	down	down	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
)	)	)	)	)	N	O
if	IN	if	if	if	N	O
possible	JJ	possible	possible	possibl	N	O
without	IN	without	without	without	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
and	CC	and	and	and	N	O
maintain	VB	maintain	maintain	maintain	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
medication	NN	medication	medication	medic	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
ICS	NNP	ics	ic	ic	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
asthma	NN	asthma	asthma	asthma	Y	O
is	VBZ	is	is	is	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
on	IN	on	on	on	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
medium	VB	medium	medium	medium	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
ICS	NNP	ics	ic	ic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
1.2	CD	1.2	1.2	1.2	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
LABA	JJ	laba	laba	laba	N	B-DrugClass
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
and	CC	and	and	and	N	O
asthma	SYM	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hospitalizations	NNS	hospitalizations	hospitalization	hospit	N	O
.	.	.	.	.	N	O

Prescribe	NNP	prescribe	prescribe	prescrib	N	O
only	RB	only	only	onli	N	O
for	IN	for	for	for	N	O
recommended	VBN	recommended	recommended	recommend	N	O
patient	NN	patient	patient	patient	N	O
populations	NNS	populations	population	popul	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
initiate	VB	initiate	initiate	initi	N	O
in	IN	in	in	in	N	O
acutely	RB	acutely	acutely	acut	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
acute	JJ	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	O
medicine	NN	medicine	medicine	medicin	N	O
containing	VBG	containing	containing	contain	N	O
a	DT	a	a	a	N	O
LABA	NNP	laba	laba	laba	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
overdose	NN	overdose	overdose	overdos	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Candida	NNP	candida	candida	candida	N	B-AdverseReaction
albicans	VBZ	albicans	albicans	albican	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
and	CC	and	and	and	N	O
pharynx	NN	pharynx	pharynx	pharynx	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
periodically	RB	periodically	periodically	period	N	O
.	.	.	.	.	N	O

Advise	VB	advise	advise	advis	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
to	TO	to	to	to	N	O
rinse	VB	rinse	rinse	rins	N	O
his	PRP$	his	his	hi	N	O
her	PRP$	her	her	her	N	O
mouth	NN	mouth	mouth	mouth	N	O
with	IN	with	with	with	N	O
water	NN	water	water	water	N	O
without	IN	without	without	without	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	O
after	IN	after	after	after	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
to	TO	to	to	to	N	O
help	VB	help	help	help	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Potential	JJ	potential	potential	potenti	N	B-Factor
worsening	NN	worsening	worsening	worsen	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
existing	VBG	existing	existing	exist	N	I-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
;	:	;	;	;	N	O
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
,	,	,	,	,	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	I-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
parasitic	JJ	parasitic	parasitic	parasit	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
;	:	;	;	;	N	O
ocular	JJ	ocular	ocular	ocular	N	I-AdverseReaction
herpes	NNS	herpes	herpes	herp	N	I-AdverseReaction
simplex	NN	simplex	simplex	simplex	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
or	CC	or	or	or	N	O
even	RB	even	even	even	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
chickenpox	NN	chickenpox	chickenpox	chickenpox	Y	B-AdverseReaction
or	CC	or	or	or	N	O
measles	NNS	measles	measles	measl	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
impaired	JJ	impaired	impaired	impair	N	B-AdverseReaction
adrenal	JJ	adrenal	adrenal	adren	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
when	WRB	when	when	when	N	O
transferring	VBG	transferring	transferring	transfer	N	O
from	IN	from	from	from	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Taper	IN	taper	taper	taper	N	O
patients	NNS	patients	patient	patient	N	O
slowly	RB	slowly	slowly	slowli	N	O
from	IN	from	from	from	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
if	IN	if	if	if	N	O
transferring	VBG	transferring	transferring	transfer	N	O
to	TO	to	to	to	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Hypercorticism	NN	hypercorticism	hypercorticism	hypercortic	N	B-AdverseReaction
and	CC	and	and	and	N	O
adrenal	JJ	adrenal	adrenal	adren	N	B-AdverseReaction
suppression	NN	suppression	suppression	suppress	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
very	RB	very	very	veri	N	O
high	JJ	high	high	high	N	O
dosages	NNS	dosages	dosage	dosag	N	O
or	CC	or	or	or	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
regular	JJ	regular	regular	regular	N	O
dosage	NN	dosage	dosage	dosag	N	O
in	IN	in	in	in	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
individuals	NNS	individuals	individual	individu	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
changes	NNS	changes	change	chang	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
slowly	RB	slowly	slowly	slowli	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

If	IN	if	if	if	N	O
paradoxical	JJ	paradoxical	paradoxical	paradox	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	O
occurs	NNS	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
and	CC	and	and	and	N	O
institute	JJ	institute	institute	institut	N	O
alternative	JJ	alternative	alternative	altern	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
beta	NN	beta	beta	beta	N	O
-	:	-	-	-	N	O
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	O
stimulation	NN	stimulation	stimulation	stimul	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
)	)	)	)	)	N	O

Assess	NNP	assess	ass	assess	N	O
for	IN	for	for	for	N	O
decrease	NN	decrease	decrease	decreas	N	O
in	IN	in	in	in	N	O
bone	JJ	bone	bone	bone	N	O
mineral	JJ	mineral	mineral	miner	N	O
density	NN	density	density	densiti	N	O
initially	RB	initially	initially	initi	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
)	)	)	)	)	N	O

Close	JJ	close	close	close	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
for	IN	for	for	for	N	O
glaucoma	NN	glaucoma	glaucoma	glaucoma	Y	O
and	CC	and	and	and	N	O
cataracts	NNS	cataracts	cataract	cataract	Y	O
is	VBZ	is	is	is	N	O
warranted	VBN	warranted	warranted	warrant	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.14	CD	5.14	5.14	5.14	N	O
)	)	)	)	)	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
convulsive	JJ	convulsive	convulsive	convuls	N	O
disorders	NNS	disorders	disorder	disord	N	O
,	,	,	,	,	N	O
thyrotoxicosis	NN	thyrotoxicosis	thyrotoxicosis	thyrotoxicosi	Y	O
,	,	,	,	,	N	O
diabetes	VBZ	diabetes	diabetes	diabet	Y	O
mellitus	NN	mellitus	mellitus	mellitu	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ketoacidosis	NN	ketoacidosis	ketoacidosis	ketoacidosi	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.15	CD	5.15	5.15	5.15	N	O
)	)	)	)	)	N	O

Be	NNP	be	be	be	N	O
alert	JJ	alert	alert	alert	N	O
to	TO	to	to	to	N	O
hypokalemia	VB	hypokalemia	hypokalemia	hypokalemia	Y	O
and	CC	and	and	and	N	O
hyperglycemia	VB	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.16	CD	5.16	5.16	5.16	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Asthma	NN	asthma	asthma	asthma	Y	O

-	:	-	-	-	N	O
Related	VBN	related	related	relat	N	O
Death	NN	death	death	death	Y	O

LABA	NNP	laba	laba	laba	N	B-DrugClass
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Currently	RB	currently	currently	current	N	O
available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
inadequate	JJ	inadequate	inadequate	inadequ	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
drugs	NNS	drugs	drug	drug	N	O
mitigates	VBZ	mitigates	mitigates	mitig	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
from	IN	from	from	from	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
.	.	.	.	.	N	O

Available	JJ	available	available	avail	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
LABA	NNP	laba	laba	laba	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
and	CC	and	and	and	N	O
adolescent	JJ	adolescent	adolescent	adolesc	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
asthma	NN	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
only	RB	only	only	onli	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
not	RB	not	not	not	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
medication	NN	medication	medication	medic	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
whose	WP$	whose	whose	whose	N	O
disease	NN	disease	disease	diseas	N	O
severity	NN	severity	severity	sever	N	O
clearly	RB	clearly	clearly	clearli	N	O
warrants	NNS	warrants	warrant	warrant	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
both	DT	both	both	both	N	O
an	DT	an	an	an	N	O
inhaled	VBN	inhaled	inhaled	inhal	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
LABA	NNP	laba	laba	laba	N	O
.	.	.	.	.	N	O

Once	RB	once	once	onc	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
is	VBZ	is	is	is	N	O
achieved	VBN	achieved	achieved	achiev	N	O
and	CC	and	and	and	N	O
maintained	VBN	maintained	maintained	maintain	N	O
,	,	,	,	,	N	O
assess	IN	assess	ass	assess	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
at	IN	at	at	at	N	O
regular	JJ	regular	regular	regular	N	O
intervals	NNS	intervals	interval	interv	N	O
and	CC	and	and	and	N	O
step	VB	step	step	step	N	O
down	RB	down	down	down	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
)	)	)	)	)	N	O
if	IN	if	if	if	N	O
possible	JJ	possible	possible	possibl	N	O
without	IN	without	without	without	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
and	CC	and	and	and	N	O
maintain	VB	maintain	maintain	maintain	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
asthma	NNS	asthma	asthma	asthma	Y	O
control	NN	control	control	control	N	O
medication	NN	medication	medication	medic	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
asthma	NN	asthma	asthma	asthma	Y	O
is	VBZ	is	is	is	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
on	IN	on	on	on	N	O
low	JJ	low	low	low	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
medium	VB	medium	medium	medium	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
28	CD	28	28	28	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
US	PRP	us	u	us	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
compared	VBN	compared	compared	compar	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
(	(	(	(	(	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
each	DT	each	each	each	N	O
added	VBD	added	added	ad	N	O
to	TO	to	to	to	N	O
usual	JJ	usual	usual	usual	N	O
asthma	NN	asthma	asthma	asthma	Y	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
showed	VBD	showed	showed	show	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
13	CD	13	13	13	N	O
,	,	,	,	,	N	O
176	CD	176	176	176	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

3	CD	3	3	3	N	O
13	CD	13	13	13	N	O
,	,	,	,	,	N	O
179	CD	179	179	179	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
;	:	;	;	;	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
:	:	:	:	:	N	O
4.37	CD	4.37	4.37	4.37	N	O
[	$	[	[	[	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
:	:	:	:	:	N	O
1.25	CD	1.25	1.25	1.25	N	O
,	,	,	,	,	N	O
15.34	CD	15.34	15.34	15.34	N	O
])	NN	])	])	])	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
LABA	NNP	laba	laba	laba	N	B-DrugClass
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
ingredients	NNS	ingredients	ingredient	ingredi	N	O
in	IN	in	in	in	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Factor
trial	NN	trial	trial	trial	N	I-Factor
adequate	NN	adequate	adequate	adequ	N	I-Factor
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
asthma	NN	asthma	asthma	asthma	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
death	NN	death	death	death	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
conducted	VBN	conducted	conducted	conduct	N	O
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	B-Factor
available	JJ	available	available	avail	N	I-Factor
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
is	VBZ	is	is	is	N	O
increased	VBN	increased	increased	increas	N	O
by	IN	by	by	by	N	O
LABA	NNP	laba	laba	laba	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Deterioration	NN	deterioration	deterioration	deterior	N	O
of	IN	of	of	of	N	O
Disease	NNP	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
Acute	NNP	acute	acute	acut	N	O
Episodes	NNP	episodes	episode	episod	N	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
rapidly	RB	rapidly	rapidly	rapidli	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
or	CC	or	or	or	N	O
potentially	RB	potentially	potentially	potenti	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	VBG	threatening	threatening	threaten	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
acutely	RB	acutely	acutely	acut	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
setting	NN	setting	setting	set	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

COPD	NNP	copd	copd	copd	Y	O
may	MD	may	may	may	N	O
deteriorate	VB	deteriorate	deteriorate	deterior	N	O
acutely	RB	acutely	acutely	acut	N	O
over	IN	over	over	over	N	O
a	DT	a	a	a	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
hours	NNS	hours	hour	hour	N	O
or	CC	or	or	or	N	O
chronically	RB	chronically	chronically	chronic	N	O
over	IN	over	over	over	N	O
several	JJ	several	several	sever	N	O
days	NNS	days	day	day	N	O
or	CC	or	or	or	N	O
longer	JJR	longer	longer	longer	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
no	RB	no	no	no	N	O
longer	JJR	longer	longer	longer	N	O
controls	VBZ	controls	control	control	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
bronchoconstriction	NN	bronchoconstriction	bronchoconstriction	bronchoconstrict	Y	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	NN	acting	acting	act	N	O
,	,	,	,	,	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
becomes	VBZ	becomes	becomes	becom	N	O
less	RBR	less	le	less	N	O
effective	JJ	effective	effective	effect	N	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
patient	JJ	patient	patient	patient	N	O
needs	VBZ	needs	need	need	N	O
more	JJR	more	more	more	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
than	IN	than	than	than	N	O
usual	JJ	usual	usual	usual	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
markers	NNS	markers	marker	marker	N	O
of	IN	of	of	of	N	O
deterioration	NN	deterioration	deterioration	deterior	N	O
of	IN	of	of	of	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
setting	VBG	setting	setting	set	N	O
a	DT	a	a	a	N	O
reevaluation	NN	reevaluation	reevaluation	reevalu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
COPD	NNP	copd	copd	copd	Y	O
treatment	NN	treatment	treatment	treatment	N	O
regimen	NNS	regimen	regimen	regimen	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
undertaken	VBN	undertaken	undertaken	undertaken	N	O
at	IN	at	at	at	N	O
once	RB	once	once	onc	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
COPD	NNP	copd	copd	copd	Y	O
,	,	,	,	,	N	O
increasing	VBG	increasing	increasing	increas	N	O
the	DT	the	the	the	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
situation	NN	situation	situation	situat	N	O
.	.	.	.	.	N	O

Increasing	VBG	increasing	increasing	increas	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
marker	NN	marker	marker	marker	N	O
of	IN	of	of	of	N	O
deteriorating	VBG	deteriorating	deteriorating	deterior	N	O
asthma	NN	asthma	asthma	asthma	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
situation	NN	situation	situation	situat	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
requires	VBZ	requires	requires	requir	N	O
immediate	JJ	immediate	immediate	immedi	N	O
reevaluation	NN	reevaluation	reevaluation	reevalu	N	O
with	IN	with	with	with	N	O
reassessment	NN	reassessment	reassessment	reassess	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
giving	VBG	giving	giving	give	N	O
special	JJ	special	special	special	N	O
consideration	NN	consideration	consideration	consider	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
need	NN	need	need	need	N	O
for	IN	for	for	for	N	O
replacing	VBG	replacing	replacing	replac	N	O
the	DT	the	the	the	N	O
current	JJ	current	current	current	N	O
strength	NN	strength	strength	strength	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
strength	NN	strength	strength	strength	N	O
,	,	,	,	,	N	O
adding	VBG	adding	adding	ad	N	O
additional	JJ	additional	additional	addit	N	O
inhaled	VBN	inhaled	inhaled	inhal	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
initiating	VBG	initiating	initiating	initi	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
acute	NN	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
rescue	NN	rescue	rescue	rescu	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	O
.	.	.	.	.	N	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
acute	NN	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
extra	JJ	extra	extra	extra	N	O
doses	NNS	doses	dos	dose	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
that	DT	that	that	that	N	O
purpose	NN	purpose	purpose	purpos	N	O
.	.	.	.	.	N	O

Acute	NNP	acute	acute	acut	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
beginning	VBG	beginning	beginning	begin	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
taking	VBG	taking	taking	take	N	O
oral	JJ	oral	oral	oral	N	O
or	CC	or	or	or	N	O
inhaled	VBN	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
regular	JJ	regular	regular	regular	N	O
basis	NN	basis	basis	basi	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
times	NNS	times	time	time	N	O
a	DT	a	a	a	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
the	DT	the	the	the	N	O
regular	JJ	regular	regular	regular	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
them	PRP	them	them	them	N	O
only	RB	only	only	onli	N	O
for	IN	for	for	for	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
healthcare	NN	healthcare	healthcare	healthcar	N	O
provider	NN	provider	provider	provid	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
prescribe	VB	prescribe	prescribe	prescrib	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
and	CC	and	and	and	N	O
instruct	VB	instruct	instruct	instruct	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
how	WRB	how	how	how	N	O
it	PRP	it	it	it	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Excessive	JJ	excessive	excessive	excess	N	O
Use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Other	JJ	other	other	other	N	O
Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
Acting	VBG	acting	acting	act	N	O
Beta2	NNP	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
Agonists	NNS	agonists	agonist	agonist	N	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
more	RBR	more	more	more	N	O
often	RB	often	often	often	N	O
than	IN	than	than	than	N	O
recommended	VBN	recommended	recommended	recommend	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
doses	NNS	doses	dos	dose	N	O
than	IN	than	than	than	N	O
recommended	VBN	recommended	recommended	recommend	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
medicines	NNS	medicines	medicine	medicin	N	O
containing	VBG	containing	containing	contain	N	O
LABA	NNP	laba	laba	laba	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
overdose	NN	overdose	overdose	overdos	Y	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
.	.	.	.	.	N	O

Clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
effects	NNS	effects	effect	effect	N	O
and	CC	and	and	and	N	O
fatalities	NNS	fatalities	fatality	fatal	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
excessive	JJ	excessive	excessive	excess	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	B-DrugClass
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
another	DT	another	another	anoth	N	O
medicine	NN	medicine	medicine	medicin	N	O
containing	VBG	containing	containing	contain	N	O
a	DT	a	a	a	N	O
LABA	NNP	laba	laba	laba	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
salmeterol	NN	salmeterol	salmeterol	salmeterol	N	O
,	,	,	,	,	N	O
formoterol	NN	formoterol	formoterol	formoterol	N	O
fumarate	NN	fumarate	fumarate	fumar	N	O
,	,	,	,	,	N	O
arformoterol	NN	arformoterol	arformoterol	arformoterol	N	O
tartrate	NN	tartrate	tartrate	tartrat	N	O
,	,	,	,	,	N	O
indacaterol	NN	indacaterol	indacaterol	indacaterol	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
reason	NN	reason	reason	reason	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Local	JJ	local	local	local	N	O
Effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
Inhaled	NNP	inhaled	inhaled	inhal	N	O
Corticosteroids	NNP	corticosteroids	corticosteroid	corticosteroid	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
localized	JJ	localized	localized	local	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
and	CC	and	and	and	N	O
pharynx	NN	pharynx	pharynx	pharynx	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
Candida	NNP	candida	candida	candida	N	I-AdverseReaction
albicans	NNS	albicans	albicans	albican	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
such	PDT	such	such	such	N	O
an	DT	an	an	an	N	O
infection	NN	infection	infection	infect	Y	O
develops	VBZ	develops	develops	develop	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
local	JJ	local	local	local	N	O
or	CC	or	or	or	N	O
systemic	JJ	systemic	systemic	system	N	O
(	(	(	(	(	N	O
i	JJ	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
)	)	)	)	)	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
while	IN	while	while	while	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
continues	VBZ	continues	continues	continu	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
at	IN	at	at	at	N	O
times	NNS	times	time	time	N	O
therapy	VBP	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
.	.	.	.	.	N	O

Advise	VB	advise	advise	advis	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
to	TO	to	to	to	N	O
rinse	VB	rinse	rinse	rins	N	O
his	PRP$	his	his	hi	N	O
her	PRP$	her	her	her	N	O
mouth	NN	mouth	mouth	mouth	N	O
with	IN	with	with	with	N	O
water	NN	water	water	water	N	O
without	IN	without	without	without	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	O
following	VBG	following	following	follow	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
to	TO	to	to	to	N	O
help	VB	help	help	help	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	O

An	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
receiving	VBG	receiving	receiving	receiv	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
pneumonias	NN	pneumonias	pneumonia	pneumonia	N	B-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
incidences	NNS	incidences	incidence	incid	N	O
these	DT	these	these	these	N	O
pneumonia	VBP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
remain	VB	remain	remain	remain	N	O
vigilant	JJ	vigilant	vigilant	vigil	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
possible	JJ	possible	possible	possibl	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
features	NNS	features	feature	featur	N	O
of	IN	of	of	of	N	O
such	JJ	such	such	such	N	O
infections	NNS	infections	infection	infect	N	O
overlap	VBP	overlap	overlap	overlap	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
COPD	NNP	copd	copd	copd	Y	O
exacerbations	NNS	exacerbations	exacerbation	exacerb	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
replicate	NN	replicate	replicate	replic	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
255	CD	255	255	255	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
experienced	VBN	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
COPD	NNP	copd	copd	copd	Y	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
previous	JJ	previous	previous	previou	N	O
year	NN	year	year	year	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
50	CD	50	50	50	N	O
mcg	NN	mcg	mcg	mcg	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
:	:	:	:	:	N	O
6%	CD	6%	6%	6%	N	O
(	(	(	(	(	N	O
48	CD	48	48	48	N	O
of	IN	of	of	of	N	O
820	CD	820	820	820	N	O
subjects	NNS	subjects	subject	subject	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
:	:	:	:	:	N	O
6%	CD	6%	6%	6%	N	O
(	(	(	(	(	N	O
51	CD	51	51	51	N	O
of	IN	of	of	of	N	O
806	CD	806	806	806	N	O
subjects	NNS	subjects	subject	subject	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
:	:	:	:	:	N	O
7%	CD	7%	7%	7%	N	O
(	(	(	(	(	N	O
55	CD	55	55	55	N	O
of	IN	of	of	of	N	O
811	CD	811	811	811	N	O
subjects	NNS	subjects	subject	subject	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
:	:	:	:	:	N	O
3%	CD	3%	3%	3%	N	O
(	(	(	(	(	N	O
27	CD	27	27	27	N	O
of	IN	of	of	of	N	O
818	CD	818	818	818	N	O
subjects	NNS	subjects	subject	subject	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	B-Negation
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
or	CC	or	or	or	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
50	CD	50	50	50	N	O
mcg	NN	mcg	mcg	mcg	N	O
25	CD	25	25	25	N	O
mcg	NN	mcg	mcg	mcg	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
subject	JJ	subject	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
7	CD	7	7	7	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
200	CD	200	200	200	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
for	IN	for	for	for	N	O
each	DT	each	each	each	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O

Persons	NNS	persons	person	person	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
using	VBG	using	using	use	N	O
drugs	NNS	drugs	drug	drug	N	B-DrugClass
that	WDT	that	that	that	N	I-DrugClass
suppress	VBP	suppress	suppress	suppress	N	I-DrugClass
the	DT	the	the	the	N	I-DrugClass
immune	NN	immune	immune	immun	N	I-DrugClass
system	NN	system	system	system	N	I-DrugClass
are	VBP	are	are	are	N	O
more	RBR	more	more	more	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
to	TO	to	to	to	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
than	IN	than	than	than	N	O
healthy	JJ	healthy	healthy	healthi	N	O
individuals	NNS	individuals	individual	individu	N	O
.	.	.	.	.	N	O

Chickenpox	NNP	chickenpox	chickenpox	chickenpox	Y	B-AdverseReaction
and	CC	and	and	and	N	O
measles	NNS	measles	measles	measl	Y	B-AdverseReaction
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
example	NN	example	example	exampl	N	O
,	,	,	,	,	N	O
can	MD	can	can	can	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
more	RBR	more	more	more	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
or	CC	or	or	or	N	O
even	RB	even	even	even	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
course	NN	course	course	cours	N	O
in	IN	in	in	in	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
children	NNS	children	child	children	N	O
or	CC	or	or	or	N	O
adults	NNS	adults	adult	adult	N	O
using	VBG	using	using	use	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	B-DrugClass
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
such	JJ	such	such	such	N	O
children	NNS	children	child	children	N	O
or	CC	or	or	or	N	O
adults	NNS	adults	adult	adult	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
had	VBN	had	had	had	N	O
these	DT	these	these	these	N	O
diseases	NNS	diseases	disease	diseas	N	O
or	CC	or	or	or	N	O
been	VBN	been	been	been	N	O
properly	RB	properly	properly	properli	N	O
immunized	VBN	immunized	immunized	immun	N	O
,	,	,	,	,	N	O
particular	JJ	particular	particular	particular	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

How	WRB	how	how	how	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
route	NN	route	route	rout	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
administration	NN	administration	administration	administr	N	O
affect	VBP	affect	affect	affect	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
a	DT	a	a	a	N	O
disseminated	JJ	disseminated	disseminated	dissemin	N	O
infection	NN	infection	infection	infect	Y	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
contribution	NN	contribution	contribution	contribut	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
prior	JJ	prior	prior	prior	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
treatment	NN	treatment	treatment	treatment	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
is	VBZ	is	is	is	N	O
also	RB	also	also	also	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
is	VBZ	is	is	is	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
chickenpox	VB	chickenpox	chickenpox	chickenpox	Y	O
,	,	,	,	,	N	O
prophylaxis	FW	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
varicella	NN	varicella	varicella	varicella	Y	O
zoster	NN	zoster	zoster	zoster	N	O
immune	JJ	immune	immune	immun	N	O
globulin	NN	globulin	globulin	globulin	Y	O
(	(	(	(	(	N	O
VZIG	NNP	vzig	vzig	vzig	N	O
)	)	)	)	)	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
is	VBZ	is	is	is	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
measles	NNS	measles	measles	measl	Y	O
,	,	,	,	,	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
pooled	JJ	pooled	pooled	pool	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	O
immunoglobulin	NN	immunoglobulin	immunoglobulin	immunoglobulin	N	O
(	(	(	(	(	N	O
IG	NNP	ig	ig	ig	N	O
)	)	)	)	)	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
See	VB	see	see	see	N	O
the	DT	the	the	the	N	O
respective	JJ	respective	respective	respect	N	O
package	NN	package	package	packag	N	O
inserts	NNS	inserts	insert	insert	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
VZIG	NNP	vzig	vzig	vzig	N	O
and	CC	and	and	and	N	O
IG	NNP	ig	ig	ig	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O
)	)	)	)	)	N	O

If	IN	if	if	if	N	O
chickenpox	JJ	chickenpox	chickenpox	chickenpox	Y	O
develops	NNS	develops	develops	develop	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
antiviral	JJ	antiviral	antiviral	antivir	N	O
agents	NNS	agents	agent	agent	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

Inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
at	IN	at	at	at	N	O
all	DT	all	all	all	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
or	CC	or	or	or	N	O
quiescent	JJ	quiescent	quiescent	quiescent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infections	NNS	infections	infection	infect	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
tract	NN	tract	tract	tract	N	O
;	:	;	;	;	N	O
systemic	JJ	systemic	systemic	system	N	O
fungal	NN	fungal	fungal	fungal	N	O
,	,	,	,	,	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	O
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
parasitic	JJ	parasitic	parasitic	parasit	N	O
infections	NNS	infections	infection	infect	N	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O
ocular	JJ	ocular	ocular	ocular	N	O
herpes	NNS	herpes	herpes	herp	N	O
simplex	NN	simplex	simplex	simplex	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Transferring	VBG	transferring	transferring	transfer	N	O
Patients	NNS	patients	patient	patient	N	O
from	IN	from	from	from	N	O
Systemic	NNP	systemic	systemic	system	N	O
Corticosteroid	NNP	corticosteroid	corticosteroid	corticosteroid	N	O
Therapy	NNP	therapy	therapy	therapi	N	O

Particular	NNP	particular	particular	particular	N	O
care	NN	care	care	care	N	O
is	VBZ	is	is	is	N	O
needed	VBN	needed	needed	need	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
transferred	VBN	transferred	transferred	transfer	N	O
from	IN	from	from	from	N	O
systemically	RB	systemically	systemically	system	N	O
active	JJ	active	active	activ	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
to	TO	to	to	to	N	O
inhaled	VB	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
because	IN	because	because	becaus	N	O
deaths	NNS	deaths	death	death	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adrenal	JJ	adrenal	adrenal	adren	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
asthma	JJ	asthma	asthma	asthma	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
transfer	NN	transfer	transfer	transfer	N	O
from	IN	from	from	from	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
to	TO	to	to	to	N	O
less	RBR	less	le	less	N	O
systemically	RB	systemically	systemically	system	N	O
available	JJ	available	available	avail	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
from	IN	from	from	from	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
months	NNS	months	month	month	N	O
are	VBP	are	are	are	N	O
required	VBN	required	required	requir	N	O
for	IN	for	for	for	N	O
recovery	NN	recovery	recovery	recoveri	N	O
of	IN	of	of	of	N	O
hypothalamic	JJ	hypothalamic	hypothalamic	hypothalam	N	O
-	:	-	-	-	N	O
pituitary	JJ	pituitary	pituitary	pituitari	N	O
-	:	-	-	-	N	O
adrenal	NN	adrenal	adrenal	adren	N	O
(	(	(	(	(	N	O
HPA	NNP	hpa	hpa	hpa	N	O
)	)	)	)	)	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
previously	RB	previously	previously	previous	N	O
maintained	VBN	maintained	maintained	maintain	N	O
on	IN	on	on	on	N	O
20	CD	20	20	20	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
(	(	(	(	(	N	O
or	CC	or	or	or	N	O
its	PRP$	its	it	it	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
)	)	)	)	)	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
most	RBS	most	most	most	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
when	WRB	when	when	when	N	O
their	PRP$	their	their	their	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
almost	RB	almost	almost	almost	N	O
completely	RB	completely	completely	complet	N	O
withdrawn	NN	withdrawn	withdrawn	withdrawn	Y	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
this	DT	this	this	thi	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
HPA	NNP	hpa	hpa	hpa	N	O
suppression	NN	suppression	suppression	suppress	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
exhibit	VB	exhibit	exhibit	exhibit	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
adrenal	JJ	adrenal	adrenal	adren	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
when	WRB	when	when	when	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
trauma	VB	trauma	trauma	trauma	Y	O
,	,	,	,	,	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
infection	NN	infection	infection	infect	Y	O
(	(	(	(	(	N	O
particularly	RB	particularly	particularly	particularli	N	O
gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
may	MD	may	may	may	N	O
control	VB	control	control	control	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	VB	asthma	asthma	asthma	Y	O
symptoms	NNS	symptoms	symptom	symptom	N	O
during	IN	during	during	dure	N	O
these	DT	these	these	these	N	O
episodes	NNS	episodes	episode	episod	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
it	PRP	it	it	it	N	O
supplies	VBZ	supplies	supply	suppli	N	O
less	RBR	less	le	less	N	O
than	IN	than	than	than	N	O
normal	JJ	normal	normal	normal	N	O
physiological	JJ	physiological	physiological	physiolog	N	O
amounts	NNS	amounts	amount	amount	N	O
of	IN	of	of	of	N	O
glucocorticoid	NN	glucocorticoid	glucocorticoid	glucocorticoid	N	O
systemically	RB	systemically	systemically	system	N	O
and	CC	and	and	and	N	O
does	VBZ	does	doe	doe	N	O
NOT	NNP	not	not	not	N	O
provide	VB	provide	provide	provid	N	O
the	DT	the	the	the	N	O
mineralocorticoid	NN	mineralocorticoid	mineralocorticoid	mineralocorticoid	N	O
activity	NN	activity	activity	activ	N	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
necessary	JJ	necessary	necessary	necessari	N	O
for	IN	for	for	for	N	O
coping	VBG	coping	coping	cope	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
emergencies	NNS	emergencies	emergency	emerg	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
periods	NNS	periods	period	period	N	O
of	IN	of	of	of	N	O
stress	NN	stress	stress	stress	Y	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
severe	JJ	severe	severe	sever	N	O
COPD	NNP	copd	copd	copd	Y	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
severe	JJ	severe	severe	sever	N	O
asthma	NN	asthma	asthma	asthma	Y	O
attack	NN	attack	attack	attack	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
from	IN	from	from	from	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
resume	VB	resume	resume	resum	N	O
oral	JJ	oral	oral	oral	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
(	(	(	(	(	N	O
in	IN	in	in	in	N	O
large	JJ	large	large	larg	N	O
doses	NNS	doses	dos	dose	N	O
)	)	)	)	)	N	O
immediately	RB	immediately	immediately	immedi	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
their	PRP$	their	their	their	N	O
physicians	NNS	physicians	physician	physician	N	O
for	IN	for	for	for	N	O
further	JJ	further	further	further	N	O
instruction	NN	instruction	instruction	instruct	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
carry	VB	carry	carry	carri	N	O
a	DT	a	a	a	N	O
warning	NN	warning	warning	warn	N	O
card	NN	card	card	card	N	O
indicating	VBG	indicating	indicating	indic	N	O
that	IN	that	that	that	N	O
they	PRP	they	they	they	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
supplementary	JJ	supplementary	supplementary	supplementari	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
during	IN	during	during	dure	N	O
periods	NNS	periods	period	period	N	O
of	IN	of	of	of	N	O
stress	NN	stress	stress	stress	Y	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
severe	JJ	severe	severe	sever	N	O
COPD	NNP	copd	copd	copd	Y	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
severe	JJ	severe	severe	sever	N	O
asthma	NN	asthma	asthma	asthma	Y	O
attack	NN	attack	attack	attack	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
requiring	VBG	requiring	requiring	requir	N	O
oral	JJ	oral	oral	oral	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
weaned	VBN	weaned	weaned	wean	N	O
slowly	RB	slowly	slowly	slowli	N	O
from	IN	from	from	from	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
use	NN	use	use	use	N	O
after	IN	after	after	after	N	O
transferring	VBG	transferring	transferring	transfer	N	O
to	TO	to	to	to	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

Prednisone	CD	prednisone	prednisone	prednison	N	O
reduction	NN	reduction	reduction	reduct	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
accomplished	VBN	accomplished	accomplished	accomplish	N	O
by	IN	by	by	by	N	O
reducing	VBG	reducing	reducing	reduc	N	O
the	DT	the	the	the	N	O
daily	JJ	daily	daily	daili	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
dose	NN	dose	dose	dose	N	O
by	IN	by	by	by	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NNS	mg	mg	mg	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
weekly	JJ	weekly	weekly	weekli	N	O
basis	NN	basis	basis	basi	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

Lung	NNP	lung	lung	lung	N	O
function	NN	function	function	function	N	O
(	(	(	(	(	N	O
FEV1or	NNP	fev1or	fev1or	fev1or	N	O
peak	VBP	peak	peak	peak	N	O
expiratory	JJ	expiratory	expiratory	expiratori	N	O
flow	NN	flow	flow	flow	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
beta	SYM	beta	beta	beta	N	O
-	:	-	-	-	N	O
agonist	NN	agonist	agonist	agonist	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	NN	asthma	asthma	asthma	Y	O
symptoms	NNS	symptoms	symptom	symptom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
monitored	VBN	monitored	monitored	monitor	N	O
during	IN	during	during	dure	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
of	IN	of	of	of	N	O
oral	JJ	oral	oral	oral	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
observed	VBN	observed	observed	observ	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
adrenal	JJ	adrenal	adrenal	adren	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
lassitude	NN	lassitude	lassitude	lassitud	Y	O
,	,	,	,	,	N	O
weakness	NN	weakness	weakness	weak	Y	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	O
and	CC	and	and	and	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
.	.	.	.	.	N	O

Transfer	NN	transfer	transfer	transfer	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
from	IN	from	from	from	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
may	MD	may	may	may	N	O
unmask	VB	unmask	unmask	unmask	N	O
allergic	JJ	allergic	allergic	allerg	N	O
conditions	NNS	conditions	condition	condit	N	O
previously	RB	previously	previously	previous	N	O
suppressed	VBN	suppressed	suppressed	suppress	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	O
,	,	,	,	,	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	O
,	,	,	,	,	N	O
eczema	NN	eczema	eczema	eczema	Y	O
,	,	,	,	,	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	O
,	,	,	,	,	N	O
eosinophilic	JJ	eosinophilic	eosinophilic	eosinophil	N	O
conditions	NNS	conditions	condition	condit	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
from	IN	from	from	from	N	O
oral	JJ	oral	oral	oral	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
experience	VB	experience	experience	experi	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
systemically	RB	systemically	systemically	system	N	O
active	JJ	active	active	activ	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
joint	JJ	joint	joint	joint	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
muscular	JJ	muscular	muscular	muscular	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
lassitude	NN	lassitude	lassitude	lassitud	Y	O
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	O
)	)	)	)	)	N	O
despite	IN	despite	despite	despit	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
or	CC	or	or	or	N	O
even	RB	even	even	even	N	O
improvement	NN	improvement	improvement	improv	N	O
of	IN	of	of	of	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Hypercorticism	NNP	hypercorticism	hypercorticism	hypercortic	N	O
and	CC	and	and	and	N	O
Adrenal	NNP	adrenal	adrenal	adren	N	O
Suppression	NNP	suppression	suppression	suppress	N	O

Inhaled	VBN	inhaled	inhaled	inhal	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
is	VBZ	is	is	is	N	O
absorbed	VBN	absorbed	absorbed	absorb	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
circulation	NN	circulation	circulation	circul	N	O
and	CC	and	and	and	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
systemically	RB	systemically	systemically	system	N	O
active	JJ	active	active	activ	N	O
.	.	.	.	.	N	O

Effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
HPA	NNP	hpa	hpa	hpa	N	O
axis	NN	axis	axis	axi	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
exceeding	VBG	exceeding	exceeding	exceed	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
dosage	NN	dosage	dosage	dosag	N	O
or	CC	or	or	or	N	O
coadministration	NN	coadministration	coadministration	coadministr	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
strong	JJ	strong	strong	strong	N	O
cytochrome	NN	cytochrome	cytochrome	cytochrom	N	O
P450	NNP	p450	p450	p450	N	O
3	CD	3	3	3	N	O
A4	NNP	a4	a4	a4	N	O
(	(	(	(	(	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
)	)	)	)	)	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
HPA	NNP	hpa	hpa	hpa	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
significant	JJ	significant	significant	signific	N	O
systemic	JJ	systemic	systemic	system	N	O
absorption	NN	absorption	absorption	absorpt	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
in	IN	in	in	in	N	O
sensitive	JJ	sensitive	sensitive	sensit	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
observed	VBN	observed	observed	observ	N	O
carefully	RB	carefully	carefully	care	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
effects	NNS	effects	effect	effect	N	O
.	.	.	.	.	N	O

Particular	JJ	particular	particular	particular	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
in	IN	in	in	in	N	O
observing	VBG	observing	observing	observ	N	O
patients	NNS	patients	patient	patient	N	O
postoperatively	RB	postoperatively	postoperatively	postop	N	O
or	CC	or	or	or	N	O
during	IN	during	during	dure	N	O
periods	NNS	periods	period	period	N	O
of	IN	of	of	of	N	O
stress	NN	stress	stress	stress	Y	O
for	IN	for	for	for	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
inadequate	JJ	inadequate	inadequate	inadequ	N	O
adrenal	JJ	adrenal	adrenal	adren	N	O
response	NN	response	response	respons	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
possible	JJ	possible	possible	possibl	N	O
that	IN	that	that	that	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
effects	NNS	effects	effect	effect	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
hypercorticism	NN	hypercorticism	hypercorticism	hypercortic	N	B-AdverseReaction
and	CC	and	and	and	N	O
adrenal	JJ	adrenal	adrenal	adren	N	B-AdverseReaction
suppression	NN	suppression	suppression	suppress	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
adrenal	JJ	adrenal	adrenal	adren	N	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
)	)	)	)	)	N	O
may	MD	may	may	may	N	B-Factor
appear	VB	appear	appear	appear	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
small	JJ	small	small	small	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
sensitive	JJ	sensitive	sensitive	sensit	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
effects	NNS	effects	effect	effect	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
effects	NNS	effects	effect	effect	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reduced	VBN	reduced	reduced	reduc	N	O
slowly	RB	slowly	slowly	slowli	N	O
,	,	,	,	,	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
accepted	JJ	accepted	accepted	accept	N	O
procedures	NNS	procedures	procedure	procedur	N	O
for	IN	for	for	for	N	O
reducing	VBG	reducing	reducing	reduc	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
treatments	NNS	treatments	treatment	treatment	N	O
for	IN	for	for	for	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	NN	asthma	asthma	asthma	Y	O
symptoms	NNS	symptoms	symptom	symptom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O
with	IN	with	with	with	N	O
Strong	NNP	strong	strong	strong	N	O
Cytochrome	NNP	cytochrome	cytochrome	cytochrom	N	O
P450	NNP	p450	p450	p450	N	O
3	CD	3	3	3	N	O
A4	NNP	a4	a4	a4	N	O
Inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O

Caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
exercised	VBN	exercised	exercised	exercis	N	O
when	WRB	when	when	when	N	O
considering	VBG	considering	considering	consid	N	O
the	DT	the	the	the	N	O
coadministration	NN	coadministration	coadministration	coadministr	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
with	IN	with	with	with	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
ketoconazole	NN	ketoconazole	ketoconazole	ketoconazol	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
known	VBN	known	known	known	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
ritonavir	NN	ritonavir	ritonavir	ritonavir	N	O
,	,	,	,	,	N	O
clarithromycin	NN	clarithromycin	clarithromycin	clarithromycin	N	O
,	,	,	,	,	N	O
conivaptan	NN	conivaptan	conivaptan	conivaptan	N	O
,	,	,	,	,	N	O
indinavir	NN	indinavir	indinavir	indinavir	N	O
,	,	,	,	,	N	O
itraconazole	NN	itraconazole	itraconazole	itraconazol	N	O
,	,	,	,	,	N	O
lopinavir	NN	lopinavir	lopinavir	lopinavir	N	O
,	,	,	,	,	N	O
nefazodone	NN	nefazodone	nefazodone	nefazodon	N	O
,	,	,	,	,	N	O
nelfinavir	RB	nelfinavir	nelfinavir	nelfinavir	N	O
,	,	,	,	,	N	O
saquinavir	NN	saquinavir	saquinavir	saquinavir	N	O
,	,	,	,	,	N	O
telithromycin	NN	telithromycin	telithromycin	telithromycin	N	O
,	,	,	,	,	N	O
troleandomycin	NN	troleandomycin	troleandomycin	troleandomycin	N	O
,	,	,	,	,	N	O
voriconazole	NN	voriconazole	voriconazole	voriconazol	N	O
)	)	)	)	)	N	O
because	IN	because	because	becaus	N	O
increased	VBN	increased	increased	increas	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
adverse	JJ	adverse	adverse	advers	N	O
effects	NNS	effects	effect	effect	N	O
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Paradoxical	JJ	paradoxical	paradoxical	paradox	N	O
Bronchospasm	NNP	bronchospasm	bronchospasm	bronchospasm	Y	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
medicines	NNS	medicines	medicine	medicin	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
can	MD	can	can	can	N	B-Factor
produce	VB	produce	produce	produc	N	O
paradoxical	JJ	paradoxical	paradoxical	paradox	N	B-AdverseReaction
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
life	NN	life	life	life	N	B-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
paradoxical	JJ	paradoxical	paradoxical	paradox	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	O
occurs	VBZ	occurs	occurs	occur	N	O
following	VBG	following	following	follow	N	O
dosing	VBG	dosing	dosing	dose	N	O
with	IN	with	with	with	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
immediately	RB	immediately	immediately	immedi	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
,	,	,	,	,	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
bronchodilator	NN	bronchodilator	bronchodilator	bronchodil	N	O
;	:	;	;	;	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
immediately	RB	immediately	immediately	immedi	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
alternative	JJ	alternative	alternative	altern	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instituted	VBN	instituted	instituted	institut	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
Including	NNP	including	including	includ	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
if	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
milk	NN	milk	milk	milk	N	O
protein	NN	protein	protein	protein	Y	O
allergy	NN	allergy	allergy	allergi	Y	O
after	IN	after	after	after	N	O
inhalation	NN	inhalation	inhalation	inhal	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
powder	NN	powder	powder	powder	N	B-DrugClass
medications	NNS	medications	medication	medic	N	I-DrugClass
containing	VBG	containing	containing	contain	N	I-DrugClass
lactose	NN	lactose	lactose	lactos	N	I-DrugClass
;	:	;	;	;	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
milk	NN	milk	milk	milk	N	O
protein	NN	protein	protein	protein	Y	O
allergy	NN	allergy	allergy	allergi	Y	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
Effects	NNS	effects	effect	effect	N	O

Vilanterol	NNP	vilanterol	vilanterol	vilanterol	N	O
,	,	,	,	,	N	O
like	IN	like	like	like	N	O
other	JJ	other	other	other	N	O
beta2	SYM	beta2	beta2	beta2	N	O
-	:	-	-	-	N	O
agonists	NNS	agonists	agonist	agonist	N	O
,	,	,	,	,	N	O
can	MD	can	can	can	N	B-Factor
produce	VB	produce	produce	produc	N	O
a	DT	a	a	a	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
effect	NN	effect	effect	effect	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
as	IN	as	a	as	N	O
measured	VBN	measured	measured	measur	N	O
by	IN	by	by	by	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
pulse	JJ	pulse	pulse	puls	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
,	,	,	,	,	N	O
systolic	NN	systolic	systolic	systol	N	I-AdverseReaction
or	CC	or	or	or	N	O
diastolic	JJ	diastolic	diastolic	diastol	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
also	RB	also	also	also	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	I-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
supraventricular	JJ	supraventricular	supraventricular	supraventricular	N	B-AdverseReaction
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	I-AdverseReaction
and	CC	and	and	and	N	O
extrasystoles	NNS	extrasystoles	extrasystole	extrasystol	Y	B-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
effects	NNS	effects	effect	effect	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
may	MD	may	may	may	N	O
need	VB	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
beta	SYM	beta	beta	beta	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
agonists	NNS	agonists	agonist	agonist	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
electrocardiographic	JJ	electrocardiographic	electrocardiographic	electrocardiograph	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
flattening	NN	flattening	flattening	flatten	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
T	NNP	t	t	t	N	I-AdverseReaction
wave	NN	wave	wave	wave	N	I-AdverseReaction
,	,	,	,	,	N	O
prolongation	NN	prolongation	prolongation	prolong	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
QTc	NNP	qtc	qtc	qtc	Y	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ST	NNP	st	st	st	N	B-AdverseReaction
segment	NN	segment	segment	segment	N	I-AdverseReaction
depression	NN	depression	depression	depress	Y	I-AdverseReaction
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Fatalities	NNS	fatalities	fatality	fatal	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
excessive	JJ	excessive	excessive	excess	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
healthy	JJ	healthy	healthy	healthi	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
large	JJ	large	large	larg	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
fluticasone	NN	fluticasone	fluticasone	fluticason	N	O
furoate	NN	furoate	furoate	furoat	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
vilanterol	NN	vilanterol	vilanterol	vilanterol	N	O
,	,	,	,	,	N	O
representing	VBG	representing	representing	repres	N	O
a	DT	a	a	a	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
higher	JJR	higher	higher	higher	N	O
systemic	JJ	systemic	systemic	system	N	O
exposure	NN	exposure	exposure	exposur	N	O
than	IN	than	than	than	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	NN	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
clinically	RB	clinically	clinically	clinic	N	B-Severity
significant	JJ	significant	significant	signific	N	I-Severity
prolongation	NN	prolongation	prolongation	prolong	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
QTc	NNP	qtc	qtc	qtc	Y	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
has	VBZ	has	ha	ha	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	B-Factor
for	IN	for	for	for	N	O
producing	VBG	producing	producing	produc	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	I-AdverseReaction
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
like	IN	like	like	like	N	O
other	JJ	other	other	other	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
amines	NNS	amines	amine	amin	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
coronary	JJ	coronary	coronary	coronari	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
.	.	.	.	.	N	O

5.13	CD	5.13	5.13	5.13	N	O
Reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
Bone	NNP	bone	bone	bone	N	O
Mineral	NNP	mineral	mineral	miner	N	O
Density	NNP	density	density	densiti	N	O

Decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
bone	JJ	bone	bone	bone	N	I-AdverseReaction
mineral	JJ	mineral	mineral	miner	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
(	(	(	(	(	N	O
BMD	NNP	bmd	bmd	bmd	N	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
products	NNS	products	product	product	N	O
containing	VBG	containing	containing	contain	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	B-DrugClass
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
significance	NN	significance	significance	signific	N	O
of	IN	of	of	of	N	O
small	JJ	small	small	small	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
BMD	NNP	bmd	bmd	bmd	N	O
with	IN	with	with	with	N	O
regard	NN	regard	regard	regard	N	O
to	TO	to	to	to	N	O
long	VB	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
consequences	NNS	consequences	consequence	consequ	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
fracture	NN	fracture	fracture	fractur	Y	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
major	JJ	major	major	major	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
decreased	JJ	decreased	decreased	decreas	N	O
bone	NN	bone	bone	bone	N	O
mineral	NN	mineral	mineral	miner	N	O
content	NN	content	content	content	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
immobilization	NN	immobilization	immobilization	immobil	N	O
,	,	,	,	,	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
,	,	,	,	,	N	O
postmenopausal	NN	postmenopausal	postmenopausal	postmenopaus	N	O
status	NN	status	status	statu	N	O
,	,	,	,	,	N	O
tobacco	NN	tobacco	tobacco	tobacco	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
advanced	JJ	advanced	advanced	advanc	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
poor	JJ	poor	poor	poor	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
chronic	JJ	chronic	chronic	chronic	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
can	MD	can	can	can	N	O
reduce	VB	reduce	reduce	reduc	N	O
bone	NN	bone	bone	bone	N	O
mass	NN	mass	mass	mass	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
anticonvulsants	NNS	anticonvulsants	anticonvulsant	anticonvuls	N	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
and	CC	and	and	and	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
established	VBN	established	established	establish	N	O
standards	NNS	standards	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
.	.	.	.	.	N	O

Since	IN	since	since	sinc	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
often	RB	often	often	often	N	O
have	VBP	have	have	have	N	O
multiple	JJ	multiple	multiple	multipl	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
reduced	JJ	reduced	reduced	reduc	N	O
BMD	NNP	bmd	bmd	bmd	N	O
,	,	,	,	,	N	O
assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
BMD	NNP	bmd	bmd	bmd	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
significant	JJ	significant	significant	signific	N	O
reductions	NNS	reductions	reduction	reduct	N	O
in	IN	in	in	in	N	O
BMD	NNP	bmd	bmd	bmd	N	O
are	VBP	are	are	are	N	O
seen	VBN	seen	seen	seen	N	O
and	CC	and	and	and	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
is	VBZ	is	is	is	N	O
still	RB	still	still	still	N	O
considered	VBN	considered	considered	consid	N	O
medically	RB	medically	medically	medic	N	O
important	JJ	important	important	import	N	O
for	IN	for	for	for	N	O
that	DT	that	that	that	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
COPD	NNP	copd	copd	copd	Y	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
medicine	NN	medicine	medicine	medicin	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
or	CC	or	or	or	N	O
prevent	VB	prevent	prevent	prevent	N	O
osteoporosis	NN	osteoporosis	osteoporosis	osteoporosi	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
strongly	RB	strongly	strongly	strongli	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

5.14	CD	5.14	5.14	5.14	N	O
Glaucoma	NNP	glaucoma	glaucoma	glaucoma	Y	O
and	CC	and	and	and	N	O
Cataracts	NNS	cataracts	cataract	cataract	Y	O

Glaucoma	NNP	glaucoma	glaucoma	glaucoma	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
intraocular	JJ	intraocular	intraocular	intraocular	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cataracts	NNS	cataracts	cataract	cataract	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	VB	asthma	asthma	asthma	Y	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
inhaled	JJ	inhaled	inhaled	inhal	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	B-DrugClass
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
close	JJ	close	close	close	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
warranted	VBN	warranted	warranted	warrant	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
vision	NN	vision	vision	vision	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	O
intraocular	JJ	intraocular	intraocular	intraocular	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
glaucoma	NN	glaucoma	glaucoma	glaucoma	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
cataracts	NNS	cataracts	cataract	cataract	Y	O
.	.	.	.	.	N	O

5.15	CD	5.15	5.15	5.15	N	O
Coexisting	NNP	coexisting	coexisting	coexist	N	O
Conditions	NNS	conditions	condition	condit	N	O

BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
,	,	,	,	,	N	O
like	IN	like	like	like	N	O
all	DT	all	all	all	N	O
medicines	NNS	medicines	medicine	medicin	N	O
containing	VBG	containing	containing	contain	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
amines	NNS	amines	amine	amin	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
convulsive	JJ	convulsive	convulsive	convuls	N	O
disorders	NNS	disorders	disorder	disord	N	O
or	CC	or	or	or	N	O
thyrotoxicosis	NN	thyrotoxicosis	thyrotoxicosis	thyrotoxicosi	Y	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
unusually	RB	unusually	unusually	unusu	N	O
responsive	JJ	responsive	responsive	respons	N	O
to	TO	to	to	to	N	O
sympathomimetic	JJ	sympathomimetic	sympathomimetic	sympathomimet	N	O
amines	NNS	amines	amine	amin	N	O
.	.	.	.	.	N	O

Doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
related	JJ	related	related	relat	N	O
beta2	NN	beta2	beta2	beta2	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
adrenoceptor	NN	adrenoceptor	adrenoceptor	adrenoceptor	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
albuterol	NN	albuterol	albuterol	albuterol	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
aggravate	VB	aggravate	aggravate	aggrav	N	B-AdverseReaction
preexisting	VBG	preexisting	preexisting	preexist	N	I-AdverseReaction
diabetes	NNS	diabetes	diabetes	diabet	Y	I-AdverseReaction
mellitus	NNS	mellitus	mellitus	mellitu	N	I-AdverseReaction
and	CC	and	and	and	N	O
ketoacidosis	NN	ketoacidosis	ketoacidosis	ketoacidosi	Y	I-AdverseReaction
.	.	.	.	.	N	O

5.16	CD	5.16	5.16	5.16	N	O
Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	O
and	CC	and	and	and	N	O
Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	O

Beta	NNP	beta	beta	beta	N	O
-	:	-	-	-	N	O
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	O
agonist	JJ	agonist	agonist	agonist	N	O
medicines	NNS	medicines	medicine	medicin	N	O
may	MD	may	may	may	N	B-Factor
produce	VB	produce	produce	produc	N	O
significant	JJ	significant	significant	signific	N	B-Severity
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
possibly	RB	possibly	possibly	possibl	N	O
through	IN	through	through	through	N	O
intracellular	JJ	intracellular	intracellular	intracellular	N	O
shunting	NN	shunting	shunting	shunt	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
has	VBZ	has	ha	ha	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
adverse	JJ	adverse	adverse	advers	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
effects	NNS	effects	effect	effect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
usually	RB	usually	usually	usual	N	O
transient	JJ	transient	transient	transient	N	O
,	,	,	,	,	N	O
not	RB	not	not	not	N	O
requiring	VBG	requiring	requiring	requir	N	O
supplementation	NN	supplementation	supplementation	supplement	N	O
.	.	.	.	.	N	O

Beta	NNP	beta	beta	beta	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
agonist	NN	agonist	agonist	agonist	N	I-DrugClass
medications	NNS	medications	medication	medic	N	I-DrugClass
may	MD	may	may	may	N	O
produce	VB	produce	produce	produc	N	O
transient	JJ	transient	transient	transient	N	B-Severity
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
evaluating	VBG	evaluating	evaluating	evalu	N	O
BREO	NNP	breo	breo	breo	N	O
ELLIPTA	NNP	ellipta	ellipta	ellipta	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
COPD	NNP	copd	copd	copd	Y	O
or	CC	or	or	or	N	O
asthma	RB	asthma	asthma	asthma	Y	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
serum	NN	serum	serum	serum	N	O
glucose	NN	glucose	glucose	glucos	Y	O
or	CC	or	or	or	N	O
potassium	NN	potassium	potassium	potassium	Y	O
.	.	.	.	.	N	O

5.17	CD	5.17	5.17	5.17	N	O
Effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
Growth	NNP	growth	growth	growth	N	O

Orally	RB	orally	orally	oral	N	B-DrugClass
inhaled	JJ	inhaled	inhaled	inhal	N	I-DrugClass
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	I-DrugClass
may	MD	may	may	may	N	O
cause	VB	cause	cause	caus	N	O
a	DT	a	a	a	N	O
reduction	NN	reduction	reduction	reduct	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
growth	NN	growth	growth	growth	N	I-AdverseReaction
velocity	NN	velocity	velocity	veloc	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.4	CD	8.4	8.4	8.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

